Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KURA NASDAQ:PHAR NASDAQ:RNAC NASDAQ:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKURAKura Oncology$10.39-0.6%$10.28$5.45▼$12.49$927.69M0.351.57 million shs1.14 million shsPHARPharming Group$12.61-4.3%$13.12$9.54▼$21.34$932.15M-0.045,866 shs5,373 shsRNACCartesian Therapeutics$7.88-0.5%$8.33$5.60▼$14.56$232.70M0.59192,137 shs143,286 shsVORVor Biopharma$19.26+1.5%$16.26$6.50▼$53.00$1.03B1.691.74 million shs638,990 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKURAKura Oncology-0.57%-4.33%-2.17%+12.20%+61.34%PHARPharming Group-4.29%-6.42%-2.89%-24.52%+22.14%RNACCartesian Therapeutics-0.51%-4.60%-18.26%+16.74%-41.15%VORVor Biopharma+1.48%+6.47%+32.81%+39.46%-53.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKURAKura Oncology$10.39-0.6%$10.28$5.45▼$12.49$927.69M0.351.57 million shs1.14 million shsPHARPharming Group$12.61-4.3%$13.12$9.54▼$21.34$932.15M-0.045,866 shs5,373 shsRNACCartesian Therapeutics$7.88-0.5%$8.33$5.60▼$14.56$232.70M0.59192,137 shs143,286 shsVORVor Biopharma$19.26+1.5%$16.26$6.50▼$53.00$1.03B1.691.74 million shs638,990 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKURAKura Oncology-0.57%-4.33%-2.17%+12.20%+61.34%PHARPharming Group-4.29%-6.42%-2.89%-24.52%+22.14%RNACCartesian Therapeutics-0.51%-4.60%-18.26%+16.74%-41.15%VORVor Biopharma+1.48%+6.47%+32.81%+39.46%-53.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKURAKura Oncology 2.69Moderate Buy$25.46145.06% UpsidePHARPharming Group 2.40Hold$38.33204.11% UpsideRNACCartesian Therapeutics 2.43Hold$32.60313.71% UpsideVORVor Biopharma 2.82Moderate Buy$42.25119.37% UpsideCurrent Analyst Ratings BreakdownLatest RNAC, KURA, VOR, and PHAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026KURAKura Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/30/2026VORVor Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/30/2026RNACCartesian Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell6/15/2026VORVor Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/15/2026KURAKura Oncology Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.006/15/2026KURAKura Oncology Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$24.006/12/2026RNACCartesian Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/10/2026RNACCartesian Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$38.006/9/2026RNACCartesian Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.006/9/2026RNACCartesian Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$44.006/4/2026KURAKura Oncology Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKURAKura Oncology$67.48M13.67N/AN/A$2.00 per share5.20PHARPharming Group$376.13M2.37$0.19 per share65.67$3.95 per share3.19RNACCartesian Therapeutics$2.80M82.68N/AN/A($4.85) per share-1.62VORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKURAKura Oncology-$278.67M-$3.35N/AN/AN/A-411.19%-141.95%-43.28%8/6/2026 (Estimated)PHARPharming Group$2.85M$0.1678.7919.39N/A3.30%4.64%2.55%7/30/2026 (Estimated)RNACCartesian Therapeutics-$130.30M-$5.90N/AN/AN/A-8,550.65%N/A-28.25%8/6/2026 (Estimated)VORVor BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest RNAC, KURA, VOR, and PHAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026KURAKura Oncology-$0.89N/AN/AN/A$20.16 millionN/A8/6/2026N/ARNACCartesian Therapeutics-$0.83N/AN/AN/A$0.18 millionN/A7/30/2026Q2 2026PHARPharming Group$0.0630N/AN/AN/A$99.52 millionN/A5/12/2026Q1 2026KURAKura Oncology-$0.88-$0.83+$0.05-$0.83$25.97 million$18.27 million5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million4/30/2026Q1 2026RNACCartesian Therapeutics-$0.84-$1.46-$0.62-$1.46$0.22 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKURAKura OncologyN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKURAKura Oncology0.096.156.14PHARPharming Group0.352.632.06RNACCartesian TherapeuticsN/A7.657.65VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKURAKura OncologyN/APHARPharming Group0.03%RNACCartesian Therapeutics86.95%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipKURAKura Oncology7.60%PHARPharming Group2.07%RNACCartesian Therapeutics37.20%VORVor Biopharma0.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKURAKura Oncology13088.77 million82.03 millionOptionablePHARPharming Group28070.78 million69.31 millionNot OptionableRNACCartesian Therapeutics6429.38 million18.45 millionOptionableVORVor Biopharma14054.19 million54.04 millionN/ARNAC, KURA, VOR, and PHAR HeadlinesRecent News About These CompaniesVor Biopharma (NASDAQ:VOR) Stock Price Up 12% - What's Next?July 21, 2026 | marketbeat.comVor Biopharma (NASDAQ:VOR) Shares Down 5% - Here's WhyJuly 20, 2026 | marketbeat.comVor Biopharma Inc. (NASDAQ:VOR) Receives Average Rating of "Moderate Buy" from AnalystsJuly 15, 2026 | americanbankingnews.comVor Biopharma Inc. (NASDAQ:VOR) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 15, 2026 | marketbeat.comVor Biopharma (NASDAQ:VOR) Stock Price Down 6.2% - What's Next?July 13, 2026 | marketbeat.comVor Biopharma: Vor Bio Appoints David Zaccardelli to Board of DirectorsJuly 8, 2026 | finanznachrichten.deVor Bio Appoints David Zaccardelli to Board of DirectorsJuly 7, 2026 | globenewswire.comVor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market RealizesJuly 7, 2026 | seekingalpha.comVor Biopharma Stock Short Interest Report | NASDAQ:VOR | BenzingaJuly 3, 2026 | benzinga.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | globenewswire.comWhy Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's NextJune 30, 2026 | finance.yahoo.comVor Biopharma: Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in ChinaJune 8, 2026 | finanznachrichten.deTelitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in ChinaJune 8, 2026 | globenewswire.comTelitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in ChinaJune 8, 2026 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comVor Bio to Participate in the 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comWe're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash WiselyMay 15, 2026 | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Protara Therapeutics (TARA), Vor Biopharma (VOR)May 14, 2026 | theglobeandmail.comVor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of MedicineMay 14, 2026 | globenewswire.comVor Biopharma: Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | finanznachrichten.deVor Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Has Real Value—But These 3 Stocks Have Better Odds Right NowBy Bridget Bennett | June 28, 2026Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and GrainsBy Bridget Bennett | July 6, 2026Why Flywire and Airbnb Could Be Quiet Winners of a CeasefireBy Nathan Reiff | July 4, 20263 Overlooked Stocks Positioned for the Next Market RotationBy Bridget Bennett | July 13, 20263 Nuclear Stocks for Investors Willing to Wait Out the DipBy Bridget Bennett | July 20, 2026RNAC, KURA, VOR, and PHAR Company DescriptionsKura Oncology NASDAQ:KURA$10.39 -0.06 (-0.57%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$10.45 +0.06 (+0.58%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Pharming Group NASDAQ:PHAR$12.60 -0.57 (-4.29%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$12.60 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Cartesian Therapeutics NASDAQ:RNAC$7.88 -0.04 (-0.51%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$8.28 +0.40 (+5.01%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.Vor Biopharma NASDAQ:VOR$19.26 +0.28 (+1.48%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$19.27 +0.01 (+0.05%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Plugging In: How Kinder Morgan Powers Up Profits TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
